LQDA
VENTE TOTALE: 90 431 titres (~6 603 860,78 $ US)
- Insiders
- Rielly-Gauvin Katherine, JEFFS ROGER
- Total bought
- —
- Total sold
- $6,603,861
- Last activity
- 2026-08-20
- Last synced
-
2026-08-26 03:23:35
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-06
LQDA presents a high-risk profile combining severe liquidity deterioration (score 40), weak fundamental momentum (score 35), and an absence of any meaningful bullish catalyst (score 25).
The first sentence of the analysis written for LQDA on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 91.6% | 58.0% | 83.5% | 82.1% | 76.5% | |
| Ebit Margin | -28.3% | -842.4% | -413.0% | -242.7% | -263.1% | |
| Ebitda Margin | -27.3% | -826.7% | -400.6% | -219.8% | -219.4% | |
| Operating Profit Margin | -32.5% | -866.6% | -419.6% | -243.3% | -263.0% | |
| Pretax Profit Margin | -43.5% | -931.7% | -448.9% | -257.4% | -269.0% | |
| Continuous Operations Profit Margin | -43.5% | -931.7% | -448.9% | -257.4% | -269.0% | |
| Net Profit Margin | -43.5% | -931.7% | -448.9% | -257.4% | -269.0% | |
| Bottom Line Profit Margin | -43.5% | -931.7% | -448.9% | -257.4% | -269.0% | |
| Current Ratio | 1.404 | 4.430 | 4.846 | 11.342 | 8.363 | |
| Quick Ratio | 1.404 | 4.425 | 4.846 | 11.342 | 8.363 | |
| Solvency Ratio | -0.238 | -0.838 | -1.074 | -0.964 | -1.018 | |
| Cash Ratio | 1.404 | 4.224 | 4.511 | 10.600 | 7.847 | |
| Price To Earnings Ratio | -43.112 | -7.084 | -9.942 | -9.507 | -6.957 | |
| Price To Earnings Growth Ratio | 0.832 | -0.190 | -0.123 | 2.218 | 0.116 | |
| Forward Price To Earnings Growth Ratio | 0.832 | -0.190 | -0.123 | 2.218 | 0.116 | |
| Price To Earnings Diluted Ratio | -43.112 | -7.084 | -9.942 | -9.507 | -6.957 | |
| Price To Earnings Diluted Growth Ratio | 0.832 | -0.190 | -0.123 | 2.218 | 0.116 | |
| Price To Book Ratio | 66.331 | 11.978 | 16.532 | 4.294 | 3.707 | |
| Price To Sales Ratio | 18.748 | 66.133 | 44.709 | 24.368 | 18.823 | |
| Price To Free Cash Flow Ratio | -74.164 | -9.409 | -18.245 | -13.307 | -7.086 | |
| Price To Operating Cash Flow Ratio | -83.175 | -9.908 | -18.811 | -13.583 | -7.108 | |
| Debt To Assets Ratio | 0.604 | 0.531 | 0.419 | 0.189 | 0.172 | |
| Debt To Equity Ratio | 4.423 | 1.584 | 1.047 | 0.271 | 0.246 | |
| Debt To Capital Ratio | 0.816 | 0.613 | 0.512 | 0.213 | 0.198 | |
| Long Term Debt To Capital Ratio | 0.748 | 0.558 | 0.479 | 0.180 | 0.138 | |
| Financial Leverage Ratio | 7.328 | 2.980 | 2.502 | 1.429 | 1.436 | |
| Working Capital Turnover Ratio | 1.597 | 0.130 | 0.215 | 0.220 | 0.237 | |
| Operating Cash Flow Ratio | -0.263 | -2.236 | -2.241 | -3.249 | -4.645 | |
| Operating Cash Flow Sales Ratio | -0.225 | -6.675 | -2.377 | -1.794 | -2.648 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.122 | 1.053 | 1.031 | 1.021 | 1.003 | |
| Debt Service Coverage Ratio | -0.523 | -3.794 | -7.882 | -14.983 | -37.014 | |
| Interest Coverage Ratio | -2.125 | -9.714 | -11.698 | -16.583 | -44.353 | |
| Short Term Operating Cash Flow Coverage Ratio | -0.611 | -5.186 | -15.894 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.180 | -0.763 | -0.839 | -1.169 | -2.117 | |
| Capital Expenditure Coverage Ratio | -8.230 | -18.877 | -32.220 | -48.291 | -318.084 | |
| Dividend Paid And Capex Coverage Ratio | -8.230 | -18.877 | -32.220 | -48.291 | -318.084 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -68.837 | -7.532 | -10.674 | -9.120 | -7.109 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 91.6% | ▲33.6% | ▲13.3% |
| Ebit Margin | -28.3% | ▲814.2% | ▲329.6% |
| Ebitda Margin | -27.3% | ▲799.4% | ▲311.5% |
| Operating Profit Margin | -32.5% | ▲834.2% | ▲332.5% |
| Pretax Profit Margin | -43.5% | ▲888.1% | ▲346.6% |
| Continuous Operations Profit Margin | -43.5% | ▲888.1% | ▲346.6% |
| Net Profit Margin | -43.5% | ▲888.1% | ▲346.6% |
| Bottom Line Profit Margin | -43.5% | ▲888.1% | ▲346.6% |
| Current Ratio | 1.405 | ▼-3.026 | ▼-4.673 |
| Quick Ratio | 1.405 | ▼-3.020 | ▼-4.672 |
| Solvency Ratio | -0.238 | ▲0.600 | ▲0.588 |
| Cash Ratio | 1.405 | ▼-2.820 | ▼-4.313 |
| Price To Earnings Ratio | -43.112 | ▼-36.028 | ▼-27.792 |
| Price To Earnings Growth Ratio | 0.832 | ▲1.023 | ▲0.262 |
| Forward Price To Earnings Growth Ratio | 0.832 | ▲1.023 | ▲0.262 |
| Price To Earnings Diluted Ratio | -43.112 | ▼-36.028 | ▼-27.792 |
| Price To Earnings Diluted Growth Ratio | 0.832 | ▲1.023 | ▲0.262 |
| Price To Book Ratio | 66.331 | ▲54.353 | ▲45.762 |
| Price To Sales Ratio | 18.748 | ▼-47.385 | ▼-15.808 |
| Price To Free Cash Flow Ratio | -74.164 | ▼-64.754 | ▼-49.721 |
| Price To Operating Cash Flow Ratio | -83.175 | ▼-73.267 | ▼-56.658 |
| Debt To Assets Ratio | 0.604 | ▲0.072 | ▲0.221 |
| Debt To Equity Ratio | 4.423 | ▲2.839 | ▲2.909 |
| Debt To Capital Ratio | 0.816 | ▲0.203 | ▲0.345 |
| Long Term Debt To Capital Ratio | 0.748 | ▲0.191 | ▲0.328 |
| Financial Leverage Ratio | 7.329 | ▲4.348 | ▲4.193 |
| Working Capital Turnover Ratio | 1.597 | ▲1.467 | ▲1.117 |
| Operating Cash Flow Ratio | -0.263 | ▲1.973 | ▲2.264 |
| Operating Cash Flow Sales Ratio | -0.225 | ▲6.449 | ▲2.518 |
| Free Cash Flow Operating Cash Flow Ratio | 1.121 | ▲0.069 | ▲0.076 |
| Debt Service Coverage Ratio | -0.523 | ▲3.270 | ▲12.316 |
| Interest Coverage Ratio | -2.125 | ▲7.589 | ▲14.769 |
| Short Term Operating Cash Flow Coverage Ratio | -0.611 | ▲4.574 | ▲3.727 |
| Operating Cash Flow Coverage Ratio | -0.180 | ▲0.583 | ▲0.833 |
| Capital Expenditure Coverage Ratio | -8.230 | ▲10.647 | ▲76.910 |
| Dividend Paid And Capex Coverage Ratio | -8.230 | ▲10.647 | ▲76.910 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -68.837 | ▼-61.306 | ▼-48.183 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $2.97B | $925.6M | $781.9M | $388.3M | $241.9M | |
| Enterprise value | $2.98B | $871.5M | $747.7M | $319.5M | $200.5M | |
| EV / Sales | 18.79x | 62.27x | 42.76x | 20.05x | 15.60x | |
| EV / Op. cash flow | -83.38x | -9.33x | -17.99x | -11.18x | -5.89x | |
| EV / Free cash flow | -74.34x | -8.86x | -17.45x | -10.95x | -5.87x | |
| EV / EBITDA | -68.84x | -7.53x | -10.67x | -9.12x | -7.11x | |
| Net debt / EBITDA | -0.17x | 0.47x | 0.49x | 1.97x | 1.47x | |
| Current ratio | 1.40x | 4.43x | 4.85x | 11.34x | 8.36x | |
| Income quality | 0.52x | 0.72x | 0.53x | 0.70x | 0.98x | |
| Graham net-net | -$1 | $0 | $0 | $1 | $1 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 154.0% | 110.6% | 108.7% | 106.0% | 102.3% | |
| Working capital | $54.9M | $143.3M | $71.3M | $91.0M | $53.9M | |
| Invested capital | $61.8M | $162.9M | $84.9M | $104.9M | $69.7M | |
| Return on assets | -21.0% | -56.6% | -66.3% | -31.7% | -36.9% | |
| Operating ROA | -18.4% | -69.6% | -59.3% | -34.8% | -35.0% | |
| Return on tangible assets | -21.5% | -58.4% | -70.7% | -33.7% | -40.5% | |
| Return on equity | -154.0% | -168.7% | -166.0% | -45.4% | -53.0% | |
| Return on invested capital | -20.5% | -58.6% | -70.9% | -31.9% | -38.6% | |
| Return on capital employed | -26.7% | -64.3% | -73.5% | -32.2% | -39.1% | |
| Earnings yield | -2.3% | -14.1% | -10.0% | -10.6% | -14.3% | |
| Free cash flow yield | -1.3% | -10.6% | -5.5% | -7.5% | -14.1% | |
| Capex / Op. cash flow | -12.2% | -5.3% | -3.1% | -2.1% | -0.3% | |
| Capex / Depreciation | 283.8% | 225.3% | 59.2% | 16.2% | 1.9% | |
| Capex / Sales | 2.7% | 35.4% | 7.4% | 3.7% | 0.8% | |
| SG&A / Sales | 99.3% | 582.8% | 255.8% | 203.4% | 179.8% | |
| R&D / Sales | 24.8% | 341.8% | 247.3% | 122.0% | 159.6% | |
| Stock comp / Sales | 18.6% | 134.4% | 57.7% | 58.3% | 52.5% | |
| Intangibles / Total assets | 2.1% | 3.1% | 6.2% | 5.9% | 8.8% | |
| Days sales outstanding | 125d | 71d | 85d | 115d | 85d | |
| Days payables outstanding | 101d | 291d | 176d | 280d | 129d | |
| Operating cycle | 125d | 86d | 85d | 115d | 85d | |
| Cash conversion cycle | 23d | -205d | -92d | -166d | -44d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+220.7%EV / Sales ▼-69.8%EV / EBITDA ▼-814.0%EV / Op. cash flow ▼-74.049Earnings yield ▲+0.118
Profitability
Return on equity ▲+0.147Return on assets ▲+0.356Return on invested capital ▲+0.381Return on capital employed ▲+0.376Operating ROA ▲+0.512Income quality ▼-0.199Tax burden 0.000
Efficiency
Days sales outstanding ▲+53.801Days payables outstanding ▼-189.739Operating cycle ▲+38.838Cash conversion cycle ▲+228.577Capex / Sales ▼-0.326R&D / Sales ▼-3.170
Balance-sheet strength
Current ratio ▼-3.026Net debt / EBITDA ▼-0.635Working capital ▼-88412000.000Invested capital ▼-101101000.000Intangibles / Total assets ▼-0.010
Change over 5 years
Valuation
Market cap ▲+1126.9%EV / Sales ▲+20.5%EV / EBITDA ▼-868.3%EV / Op. cash flow ▼-77.486Earnings yield ▲+0.120
Profitability
Return on equity ▼-1.010Return on assets ▲+0.159Return on invested capital ▲+0.182Return on capital employed ▲+0.124Operating ROA ▲+0.166Income quality ▼-0.467Tax burden 0.000
Efficiency
Days sales outstanding ▲+39.799Days payables outstanding ▼-27.813Operating cycle ▲+39.799Cash conversion cycle ▲+67.612Capex / Sales ▲+0.019R&D / Sales ▼-1.348
Balance-sheet strength
Current ratio ▼-6.959Net debt / EBITDA ▼-1.636Working capital ▲+963000.000Invested capital ▼-7904000.000Intangibles / Total assets ▼-0.068
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-24 Will LQDA''s Differentiated PAH Approach Drive Growth? LQDA''s Yutrepia is driving rapid growth, but intensifying PAH competition could test its ability to sustain momentum.
- 2026-08-20 Liquidia Corp (LQDA) Shares Fall 5.8% -- What GF Score of 70 Tells Investors On August 20, 2026, Liquidia Corp (LQDA) shares fell 5.8% to $71.05, continuing a downward trend from its 52-week high of $93.61, while still reflecting a subst
- 2026-08-19 Can Yutrepia''s Strong Growth Drive Liquidia''s PAH Expansion? Liquidia''s Yutrepia is gaining traction, with $300.3M in first-half sales and nearly 30% of inhaled-market revenues in Q2.
- 2026-08-18 Handelsbanken Fonder AB Invests $1.99 Million in Liquidia Corporation $LQDA Handelsbanken Fonder AB bought a new stake in Liquidia Corporation (NASDAQ: LQDA) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 25,000 shares of the company''s stock, valued at approximately $1,993,000. Other institutional investors and hedge funds
- 2026-08-17 LQDA Stock Down Post Q2 Earnings Release: What Should Investors Do Now? Liquidia''s Yutrepia is fueling rapid growth, but patent litigation, competition and heavy product dependence weigh on its outlook.
- 2026-08-14 Why Liquidia Stock Was Diving This Week The shares had risen by 155% year-to-date prior to earnings. Regardless, its one commercialized drug is doing well by any measure.
- 2026-08-13 LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth Yutrepia sales fuel Liquidia''s Q2 growth as revenues surge and profitability rises, while the company targets more than $1 billion in 2027 revenues.
- 2026-08-13 LQDA Q2 Earnings Call Highlights YUTREPIA and $1B 2027 Revenue Path Liquidia targets more than $1 billion in 2027 net revenues as YUTREPIA gains share and funds a broader inhaled-treprostinil pipeline.
- 2026-08-13 Liquidia: YUTREPIA''s Launch Opens Upside If Growth Remains And Margins Follow YUTREPIA''s commercial launch continues to scale, with Q2 product sales of $170.4 million, up 31% sequentially. Q2 largely resolved the margin concern: product gross margin remained about 93.7% despite fully costed inventory, while operating margin reached roughly 49.8%. The key debate has shifted from profitability to growth. Liquidia now needs about $210 million of quarterly revenue in Q3 and Q4 to reach the current $725 million FY2026 consensus.
- 2026-08-12 Liquidia Corporation (LQDA) Q2 2026 Earnings Call Transcript Liquidia Corporation (LQDA) Q2 2026 Earnings Call Transcript